Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
Links shared publicly online about this topic.
- 755total visits
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
View full resource at novartis.com
Tags: COPD, COPD Medication, Drug, Spiriva, Novartis
Most Recently Shared on November 3, 2010 at 7:44 am By:
Client? RT @DanBax76: RT@Novartis: http://bit.ly/cN61nM <interesting
Also Shared By:
Onbrez Breezhaler From Novartis Provides Greater Clinical Benefits Than Tiotropium in New Study of COPD Patients - Drugs.com MedNews
drugs.com — “Study shows Onbrez Breezhaler superior to tiotropium in reducing breathlessness and use of rescue medication and in improving overall health status 1 INTENSITY” View full resource at drugs.com
Most Recently Shared on November 3, 2010 at 3:09 pm By:
Drugs and Devices OW OW Health
Onbrez Breezhaler From Novartis Provides Greater Clinical Benefits Than Tiotropium in New Study of COPD Patie... http://bit.ly/ab5rWP #drug
Advertisement
Novartis
@Novartis
INTENSITY study presented at #CHEST10 adds to existing data about Novartis COPD drug http://bit.ly/cN61nM
1 year ago...